A prespecified sub-group analysis of the PRACTICAL study in patients with asthma showed that the reduction in severe exacerbation risk with budesonide-formoterol reliever compared with maintenance budesonide was similar in Māori and Pacific adults compared with New Zealand European/Other. Of 890 adults with mild to moderate asthma enrolled in the study, 72 (8%) identified as Māori and 36 (4%) as Pacific. There was no evidence of an ethnicity-treatment interaction for severe exacerbations of asthma.www.facebook.com/tekareremaorinews/videos/2668876773327946